A few years ago, multinational pharma companies seeking growth and respite from market uncertainty in Europe and the United States found a haven in emerging markets. Their rapid economic growth triggered an expansion in healthcare coverage and the emergence of a new cohort of consumers able to afford larger out-of-pocket spending on drugs. But early euphoria was soon replaced by a more somber outlook.
{iframe}http://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/whats-next-for-pharma-in-emerging-markets?cid=other-eml-alt-mip-mck-oth-1706&hlkid=da8da8924b9541d287459c206e5d5910&hctky=3027237&hdpid=9e83f79d-0a47-4c91-ba91-dcc2ad4a94d2{/iframe}